Top

International Journal of Clinical Oncology

Published in:

01-02-2010 | Original Article

Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study

Authors: Keiichiro Ishibashi, Norimichi Okada, Tatsuya Miyazaki, Motohiko Sano, Hideyuki Ishida

Published in: International Journal of Clinical Oncology | Issue 1/2010

Abstract

Background

Whether the administration of calcium (Ca) and magnesium (Mg) can reduce oxaliplatin-related neurotoxicity remains controversial. In addition, little is known about the effects of Ca/Mg on the blood level of platinum or objective tumor progression.

Patients and methods

Patients receiving modified FOLFOX6 for metastatic colorectal cancer were double-blinded and randomized to receive additional treatment with Ca/Mg or placebo before and after the administration of oxaliplatin. The plasma and ultrafiltrable concentrations of platinum during the first and fifth cycles of treatment were determined using inductively coupled plasma spectrometry.

Results

Patients were randomized to receive Ca/Mg (Ca/Mg group, n = 17) or placebo (placebo group, n = 16) before and after the administration of oxaliplatin (85 mg/m²). The incidence of neurotoxicity after six cycles was not significantly different between the two groups. Blood concentrations of platinum at each time and the area under the curve were also not significantly different between the two groups. Furthermore, the response rate (RR) and disease control rate (DCR) did not differ significantly between the two groups (Ca/Mg group: RR 36%, DCR 73%. Placebo group: RR 40%, DCR 70%, P > 0.99). The median progression-free survival time was 9.2 months in the Ca/Mg group and 8.1 months in the control group; these survival times were not significantly different (P = 0.56).

Conclusion

These data are insufficient to conclude with any certainty that the administration of Ca/Mg is not neuroprotective; however, the administration of Ca/Mg may not have any influence on antitumor activity and the blood concentration profile of platinum in patients receiving oxaliplatin-based chemotherapy.

Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237CrossRefPubMed

de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMed

Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreatment metastatic colorectal cancer. J Clin Oncol 22:23–30CrossRefPubMed

Land SR, Kopec JA, Cecchini RS et al (2007) Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer:NSABP C-07. J Clin Oncol 25:2205–2211CrossRefPubMed

Gamelin L, Boisdron-Celle M, Delva R et al (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055–4061CrossRefPubMed

Hochster HS, Grothey A, Childs BH (2007) Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 25:4028–4029CrossRefPubMed

Gamelin L, Boisdron-Celle M, Morel A et al (2008) Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 26:1188–1189CrossRefPubMed

Grothey A, Hart LL, Rowland KM et al (2008) Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial. Proc Am Soc Clin Oncol 26(abstr 4010)

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216CrossRefPubMed

10.

National Cancer Institute. National Cancer Institute Common Toxicity Criteria version 3.0. http://ctep.cancer.gov/

11.

Levi F, Perpoint B, Garufi C et al (1993) Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 29:1280–1284CrossRef

12.

Lévi F, Metzger G, Massari C et al (2000) Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 38:1–21CrossRefPubMed

13.

Nikcevich DA, Grothey A, Sloan JA et al (2008) Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: results of the phase III placebo-controlled, double-blind NCCTG trial N04C7. Proc Am Soc Clin Oncol 26(abstr 4009)

14.

Tournigand C, Cervantes A, Figer A et al (2006) OPTMOX1: a randomized study of FOFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—A GERCOR study. J Clin Oncol 24:394–400CrossRefPubMed

15.

Petrioli R, Pascucci A, Francini E et al (2008) Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol 61:105–111CrossRefPubMed

16.

Graham MA, Lockwood GF, Greenslade D et al (2000) Clinical pharmacokinetics of oxaliplatin: a clinical review. Clin Cancer Res 6:1205–1218PubMed

17.

Shirao K, Matsumura Y, Yamada Y et al (2006) Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors. Jpn J Clin Oncol 36:295–300CrossRefPubMed

Title: Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study
Authors: Keiichiro Ishibashi
Norimichi Okada
Tatsuya Miyazaki
Motohiko Sano
Hideyuki Ishida
Publication date: 01-02-2010
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 1/2010
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-009-0015-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer

A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain

Amputation of uterine corpus as the intraoperative modification during cesarean radical hysterectomy for invasive cervical cancer during pregnancy

Treatment results of FOLFOX chemotherapy before surgery for lymph node metastasis of advanced colorectal cancer with synchronous liver metastasis: the status of LN metastasis and vessel invasions at the primary site in patients who responded to FOLFOX

Successful treatment for metastases from renal cell carcinoma with alternation of interferon-alpha subtypes

Erratum to: Thymic squamous cell carcinoma producing granulocyte colony-stimulating factor associated with a high serum level of interleukin 6

Keynote webinar | Spotlight on antibody–drug conjugates in cancer